A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 26394669.
- Also identified by DOI 10.1093/cid/civ841 and PMC identifier 4690485.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.
Medical subject headings
- Immune Reconstitution Inflammatory Syndrome
- Immunologic Factors
- Infliximab
- Tuberculosis